Bryan D Fleming

Title: Innovations of Bryan D Fleming in Monoclonal Antibodies

Introduction

Bryan D Fleming is a notable inventor based in Bethesda, MD (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on targeting glypican-2, a protein that plays a crucial role in various cancers.

Latest Patents

Bryan D Fleming holds a patent for "High affinity monoclonal antibodies targeting glypican-2 and uses thereof." This patent describes monoclonal antibodies that bind glypican-2 (GPC2) with high affinity. The patent further details immunotoxins and chimeric antigen receptors (CARs) that incorporate these antibodies or their antigen-binding fragments. In some cases, the antibodies or fragments are humanized. The GPC2-specific antibodies and conjugates disclosed in this patent can be utilized for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma, and retinoblastoma. He has 1 patent to his name.

Career Highlights

Bryan D Fleming is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this prestigious institution allows him to contribute to groundbreaking research in cancer treatment and diagnostics.

Collaborations

Some of his notable coworkers include Mitchell Ho and Nan Li. Their collaborative efforts enhance the research and development of innovative therapies targeting cancer.

Conclusion

Bryan D Fleming's work in developing high-affinity monoclonal antibodies represents a significant advancement in cancer treatment. His contributions to the field are invaluable and continue to pave the way for future innovations in biotechnology.